SUPRAME enrollment completion by year-end and H1 2027 PFS data are the key catalysts. Cash runway into Q4 2028 reduces near-term financing risk. Monitor BLA submission timing in 2027.
Drugs in focus
IMTX drug pipeline →IMA203
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 succeeds, BLA submission is planned for 2027 with a potential commercial launch in 2027-2028.
- Next catalyst
- None dated
What to watchThe binary catalyst is the SUPRAME Phase 3 final PFS readout in H1 2027. Positive data would validate anzu-cel for BLA submission in 2027 and could drive significant upside toward analyst targets (~$17). A negative or underwhelming result would likely hit the stock hard given its current single-asset weighting. Interim operational updates on enrollment could come at the Q3 earnings call on Nov 16, 2026.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $6.42entry
- T+1 · 6d ago +4.21%α +2.89% · $6.69
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immatics reported Q3 2026 net loss of $86.3M (€76.0M), wider than the $57.3M loss a year ago, driven by higher R&D costs for the SUPRAME Phase 3 trial. Revenue from collaborations rose to $7.8M from $5.9M. Cash of $536.3M extends runway into Q4 2028, and the company reiterated SUPRAME enrollment completion by year-end with topline PFS data in H1 2027.
Key Financial Metrics
Key Facts
- Net loss of $86.3M (€76.0M) for Q3 2026 vs $57.3M loss in Q3 2025
- Revenue from collaborations $7.8M (€6.9M) vs $5.9M in Q3 2025
- Cash and financial assets $536.3M (€472.3M) as of Sep 30, 2026; cash reach into Q4 2028
- SUPRAME Phase 3 enrollment on track to complete by year-end; topline PFS data expected H1 2027
- R&D expenses $79.8M (€70.3M) vs $53.6M in Q3 2025, driven by SUPRAME trial costs
- Net loss per ADS (basic and diluted) €0.50 for Q3 2026 vs €0.42 in Q3 2025
Financial Impact
Net loss widened by $29M YoY; cash position essentially flat after $197.5M in gross offering proceeds offset by R&D spending
Risk Factors
- Phase 3 SUPRAME trial may fail to meet PFS endpoint, delaying or preventing approval
- Net loss growing faster than revenue; cash burn rate increased significantly in Q3 2026
- Regulatory and commercial execution risks for anzu-cel launch
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3399294 |
Track record
23 reports on IMTX
8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 5/10 No price data
- Nov 10, 20266d ago Press Release Neutral 4/10 Viewing Entry $6.42 Now $6.17 −3.89% settles Nov 17
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
- Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
- Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
- Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers